VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Key factors to consider for TKI discontinuation in CML

Camille Kockerols, MD, Albert Schweitzer Hospital, Dordrecht, Netherlands, talks about the challenges faced when attempting tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML), highlighting the two factors currently used to consider TKI discontinuation, including treatment and deep molecular response (DMR) duration, but also suggests that further factors should be measured to help determine the optimal timing for TKI discontinuation. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter